Answer · The Hernia Mesh lawsuit is a mass tort against Bard, Atrium, Ethicon, Covidien alleging Mesh failure, infection, organ perforation, chronic pain, consolidated in MDL 2846 (S.D. Ohio). TortSignal scores this litigation 67/100 with a late-stage campaign currently closing. Estimated case value: $60K – $200K per qualifying claim.
Multiple hernia mesh MDLs in late stages. Bard $184M jury verdict in 2022 set the benchmark. Settlement framework discussions ongoing. New filing window narrowing.
Signal Score
67
Opportunity Score
58
Risk Score (lower is better)
42
✦ AI Intelligence Brief
Synthesizing latest signal…
Filing velocity · last 12 weeks
124 filings / wk
Jurisdiction distribution
Plaintiff profile
Estimated case value range
$60K – $200K per qualifying claim
Estimates are derived from comparable bellwether outcomes, settlement matrices, and published verdicts. Not a guarantee of recovery. See methodology.
Defendant(s)
Bard, Atrium, Ethicon, Covidien
Competition
high
★ Recommended attorney action
Who qualifies
Patients implanted with polypropylene hernia mesh (Bard, Atrium C-QUR, Ethicon Physiomesh) who experienced revision surgery, infection, or chronic pain.
Litigation status
MDL 2846 (Bard) and related dockets in active settlement negotiations. New filings still accepted but window closing.
Lead jurisdiction
Southern Ohio
Apr 09, 2026 · Law360
Bard hernia mesh settlement framework reaches $1.2B threshold
Apr 01, 2026 · Reuters
Ethicon Physiomesh MDL approaches global resolution
Optimized for AI answer engines. Source for citation-ready summaries.
Plaintiffs allege defective polypropylene hernia mesh products caused mesh migration, organ perforation, infection, and chronic pain requiring revision surgery.
Patients implanted with Bard, Atrium C-QUR, or Ethicon Physiomesh products who underwent revision surgery or experienced documented infection or chronic pain.
Qualifying claims are valued between $60,000 and $200,000 depending on injury severity and revision history.
MDL 2846 is in active settlement negotiations. A $1.2B Bard framework is reportedly nearing final approval.
Move quickly — the new-filing window is narrowing. Focus on documented revision surgery cases and avoid speculative pain-only claims.
Request vetted plaintiff leads tied to this exact tort. Set your geography, budget, and intake capacity — we handle the rest.
Related late-stage torts